Massachusetts-based biotech Karyopharm Therapeutics said it has lowered the dosage of its lead cancer drug in an ongoing mid-stage trial due to concerns about a higher-than expected incidence of sepsis.
Karyopharm disclosed that last month it amended a Phase 2 study of selinexor in patients with acute myeloid leukemia, after eight reported cases of sepsis in the 150 patient trial. The original dose of 55 milligrams per square meter of body surface area has been reduced to 35 mg.
The company now expects an interim assessment mid-2016, with final results expected toward the end of 2016.
Read the Boston Business Journal article